Business Wire

THALES

7.10.2019 07:47:05 CEST | Business Wire | Press release

Share
The Cyberthreat Handbook: Thales and Verint Release Their "Who's Who" of Cyberattackers

Powered by the cutting-edge technologies and products of Thales and Verint, the two companies are pleased to present The Cyberthreat Handbook , a report of unprecedented scope designed to provide a classification and basis for further investigation of major groups of cyberattackers, including cybercriminals, cyberterrorists, hacktivist groups and state-sponsored hackers. As part of the strategic partnership to create a comprehensive, state-of-the art Cyber Threat Intelligence technologies, threat intelligence analysts from Thales and Verint have worked together to provide this unique 360° view of the cyberthreat landscape, with detailed descriptions of the activities of about sixty particularly significant groups, including their tactics and techniques, their motives and the sectors targeted from analysis of multiple data sources such as web and threat intelligence.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191006005044/en/

As cybersecurity grows in importance, Thales and Verint have worked together to find out more about cyberattackers and the techniques they employ, the purpose being to help organisations in the private and public sectors to better detect and anticipate future attacks. The cyberthreat landscape is extremely diversified, and knowing one's enemies can be particularly complex in this world of subterfuge and deception.

"The Thales and Verint teams are immensely proud to release this report today as part of its technology and domain expertise cooperation. Unique in its breadth and depth, it is the culmination of many months of research, investigation and painstaking analysis and correlation of relevant data. As cyberthreats proliferate and evolve, cybersecurity clearly has a major role to play, particularly for critical infrastructure providers. It is our duty to analyse, understand and describe the techniques employed by cyberattackers so that our customers and all other businesses and organisations are better prepared to detect and anticipate future attacks." Marc Darmon, Executive Vice President, Secure Communications and Information Systems, Thales

“Joining forces with Thales strengthens our mutual ability to deliver comprehensive knowledge of potential threats, and thus provide the necessary cyber security protection,” said Elad Sharon, President, Verint Cyber Intelligence Solutions. “Verint Cyber Intelligence leverages years of intelligence domain expertise, embedded within investigation methodologies and technologies critical to prevent cyber-attacks before they get into the gateway of the organization. This report generates unique insights and knowldege to cyber and security experts to mitigate and foresee cyberattacks”.

Analysts from Thales and Verint have defined four major categories of attackers based on their motives and ultimate objectives. Out of approximately sixty major groups of attackers analysed, 49% are state-sponsored groups often aiming to steal sensitive data from targets of geopolitical interest. 26% are ideologically motivated hacktivists, closely followed by cybercriminals (20%) who are driven by financial gain. In fourth position, cyberterrorists account for 5% of the groups analysed.

All the world's major economic, political and military powers are priority targets of cyberattackers. The 12 countries in the world with the highest GDP are all at the top of the list of targets, headed by the United States, Russia, the European Union (particularly the United Kingdom, France and Germany) and China, followed by India, South Korea and Japan.

The sectors most targeted by these major attacks are States and their defence capabilities, followed by the financial sector, energy and transportation. Attacks towards medias and health industry are increasing fast.

Last but not least, a growing number of groups of attackers are now focusing on vulnerabilities in the supply chain, and in particular on smaller partners, suppliers and service providers that are used as trojans to access major targets.

Notes to editors - Methodology

This report does not set out to be an exhaustive inventory of cyberattackers but rather to shed light on the major groups of attackers that have been identified over the last 10 years. The sixty-odd groups and 490 attack campaigns analysed in the report were selected because they are considered emblematic in terms of their impact, attack techniques, scope, target profiles, historical nature or recent emergence. The entire analysis is based on the MITRE Att&ck matrix , a knowledge base of adversary tactics and techniques. More details can be found in the press kit.

 

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €19 billion in 2018 (on a pro forma basis including Gemalto).

 

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments

 

About Verint Systems Inc.

Verint® (Nasdaq: VRNT) is a global leader in Actionable Intelligence® solutions with a focus on customer engagement optimisation, security intelligence, and fraud, risk and compliance. Today, over 10,000 organisations in more than 180 countries—including over 80 percent of the Fortune 100—count on intelligence from Verint solutions to make more informed, effective and timely decisions. Learn more about how we’re creating A Smarter World with Actionable Intelligence® at www.verint.com .

 

About Verint Cyber Intelligence.

Verint Cyber Intelligence is a leading global provider of security and intelligence data mining software. Our broad and deep product portfolio is deployed in over 100 countries, helping government, critical infrastructure and enterprise organizations to neutralize and prevent terror, crime and cyber threats for a safer world.

PLEASE VISIT

Thales Group
Download photos
Download the report

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye